- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nothing to disclose on Cipla stake buy report, says Torrent Pharma
Bengaluru: India's Torrent Pharmaceuticals on Friday said it has no information requiring disclosure under listing regulations, after the Economic Times reported that it was in talks to buyout the stake of rival Cipla's top shareholders.
Torrent said it "did not comment on speculative reports in the absence of verified data," and that it was not in a position to comment on the movement in its share price.
Torrent Pharma is interested in buying out top shareholder Hamied family's 33.47 per cent stake in Cipla and is trying to put together financing for the purchase, ET reported.
The company has reached out to private equity firms including Advent International, Bain Capital, Warburg Pincus and CVC Capital, for a minority stake in a consortium, the ET report said.
Additionally, it is also in talks with foreign banks such as Standard Chartered and JP Morgan for acquisition financing, and domestic shadow banks and mutual funds in share-backed promoter financing, the report added.
Cipla, which makes anti-allergic drug Cetirizine and generic versions of respiratory drugs Advair and Albuterol, had in July issued a clarification saying there is no information to disclose as per listing regulations regarding a stake sale
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story